Bryan has more than 15 years’ experience in clinical outcome assessments (COAs) within academia, clinical practice, the pharmaceutical industry, and consultancy. He has experience in a wide range of therapeutic areas including oncology, respiratory, immunology, rheumatology and neurology. He provides strategic leadership on projects involving the identification, modification, development, validation and implementation of COAs fit for regulatory purposes and that of other stakeholders. Bryan has a keen interest in rare disease, enhancing patient centricity in the drug development process and throughout the lifecycle of drug products, and helping clients differentiate their products through novel COAs.
He has published research and presented at international conferences in a number of areas including patient preference and clinical outcomes, health-related quality of life and individualised health-related quality of life. He holds a PhD from Bangor University, a first class BSc (Hons) degree from Glasgow Caledonian University, and is a Chartered Psychologist and Associate Fellow of the British Psychological Society. He is also involved in ISPOR SIG for rare diseases and medication adherence.
During his free time Bryan enjoys spending time with his two dogs (Max and Monty) on the beautiful beaches of Anglesey, the mountains in Snowdonia and the North West Wales coastline.